GH

Guardant Health Stock Price

124.71
3.77 (3.12%)
Upgrade to Real-Time
Regular Market
124.71

Low
75.49

52 Week Range

High
181.07

Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
Guardant Health Inc GH NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
3.77 3.12% 124.71 13:18:19
Open Price Low Price High Price Close Price Prev Close
121.54 121.30 125.20 120.94
Bid Price Ask Price Spread News
124.64 124.81 0.17 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
6,790 380,734 $ 123.84 $ 47,149,977 1,093,915 75.49 - 181.07
Last Trade Time Type Quantity Stock Price Currency
13:18:19 10 $ 124.71 USD

Guardant Health Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 12.61B 101.12M 96.62M $ 286.73M $ -285.50M -2.58 -35.80
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -787.79k 4.40%

more financials information »

Guardant Health News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical GH Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week116.61125.20113.26117.111,466,1378.106.95%
1 Month112.66128.44110.33118.721,019,31712.0510.7%
3 Months145.11169.425108.03134.86947,636-20.40-14.06%
6 Months125.66181.07108.03141.661,034,334-0.95-0.76%
1 Year75.88181.0775.49121.62972,91248.8364.35%
3 Years27.75181.0727.0489.971,017,03196.96349.41%
5 Years27.75181.0727.0489.971,017,03196.96349.41%

Guardant Health Description

Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company's pipeline includes Lunar-1, for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.


Your Recent History
NASDAQ
GH
Guardant H..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.